AFMD:NSD-Affimed N.V (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.41

Change

0.00 (0.00)%

Market Cap

USD 0.34B

Volume

1.17M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which has completed Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager for the treatment of advanced cancer patients; AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific antibodies for the treatment of multiple myeloma. In addition, it is developing AFM11, a T cell engager for the treatment of CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb that is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Corporation; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-11 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD76.34B 51.29 38.52
REGN Regeneron Pharmaceuticals, Inc

N/A

USD63.70B 32.18 22.32
SGEN Seattle Genetics, Inc

N/A

USD30.18B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.03B 10.20 8.76
MRNA Moderna, Inc

N/A

USD23.24B N/A N/A
GMAB Genmab A/S

N/A

USD22.91B 49.21 4.63
BMRN BioMarin Pharmaceutical Inc

N/A

USD22.80B 201.29 120.75
INCY Incyte Corporation

N/A

USD22.77B 47.64 35.20
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD18.63B N/A N/A
BGNE BeiGene, Ltd

N/A

USD15.57B N/A N/A

ETFs Containing AFMD

Symbol Name Weight Mer Price(Change) Market Cap
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD0.21B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 60.95% 81% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.95% 81% B- 89% B+
Trailing 12 Months  
Capital Gain 40.89% 68% D+ 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.89% 68% D+ 82% B-
Trailing 5 Years  
Capital Gain -72.25% 36% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.25% 36% F 14% F
Average Annual (5 Year Horizon)  
Capital Gain -0.30% 49% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.30% 48% F 25% F
Risk Return Profile  
Volatility (Standard Deviation) 59.63% 31% F 15% F
Risk Adjusted Return -0.50% 51% F 30% F
Market Capitalization 0.34B 53% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 9.54 22% F 14% F
Price / Cash Flow Ratio -11.57 70% C- 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -115.13% 27% F 11% F
Return on Invested Capital -75.93% 39% F 12% F
Return on Assets -26.17% 58% F 16% F
Debt to Equity Ratio 0.72% 84% B 91% A-
Technical Ratios  
Short Ratio 0.96 69% D+ 73% C
Short Percent 2.59% 69% D+ 56% F
Beta 2.88 5% F 4% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector